PALB2 and cancer: Future studies assessing aberrant PALB2 lysine acetylation in cancer tissues and whether KDAC or bromodomain inhibitors, currently in clinical trials for cancer therapy, would modulate PALB2 acetylation may offer therapeutic potential.